



# Cabinet Office

## CARBON REDUCTION PLAN GUIDANCE

### Notes for Completion

Where an In-Scope Organisation has determined that the measure applies to the procurement, suppliers wishing to bid for that contract are required at the selection stage to submit a Carbon Reduction Plan which details their organisational carbon footprint and confirms their commitment to achieving Net Zero by 2050.

Carbon Reduction Plans are to be completed by the bidding supplier<sup>1</sup> and must meet the reporting requirements set out in supporting guidance, and include the supplier's current carbon footprint and its commitment to reducing emissions to achieve Net Zero emissions by 2050.

The CRP should be specific to the bidding entity, or, provided certain criteria are met, may cover the bidding entity and its parent organisation. In order to ensure the CRP remains relevant, a Carbon Reduction Plan covering the bidding entity and its parent organisation is only permissible where the detailed requirements of the CRP are met in full, as set out in the Technical Standard<sup>2</sup> and Guidance<sup>3</sup>, and all of the following criteria are met:

- The bidding entity is wholly owned by the parent;
- The commitment to achieving net zero by 2050 for UK operations is set out in the CRP for the parent and is supported and adopted by the bidding entity, demonstrated by the inclusion in the CRP of a statement that this will apply to the bidding entity;
- The environmental measures set out are stated to be able to be applied by the bidding entity when performing the relevant contract; and
- The CRP is published on the bidding entity's website.

Bidding entities must take steps to ensure they have their own CRP as soon as reasonably practicable and should note that the ability to rely on a parent organisation's Carbon Reduction Plan may only be a temporary measure under this selection criterion.

The Carbon Reduction Plan should be updated regularly (at least annually) and published and clearly signposted on the supplier's UK website. It should be approved by a director (or equivalent senior leadership) within the supplier's organisation to demonstrate a clear commitment to emissions reduction at the highest level. Suppliers may wish to adopt the key objectives of the Carbon Reduction Plan within their strategic plans.

A template for the Carbon Reduction Plan is set out below. Please complete and publish your Carbon Reduction Plan in accordance with the reporting standard published alongside this PPN.

---

<sup>1</sup> Bidding supplier or 'bidding entity' means the organisation with whom the contracting authority will enter into a contract if it is successful.

<sup>2</sup> Technical Standard can be found at:

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/991625/PPN\\_0621\\_Technical\\_standard\\_for\\_the\\_Completion\\_of\\_Carbon\\_Reduction\\_Plans\\_\\_2\\_.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/991625/PPN_0621_Technical_standard_for_the_Completion_of_Carbon_Reduction_Plans__2_.pdf)

<sup>3</sup> Guidance can be found at:

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/991623/Guidance\\_on\\_adopting\\_and\\_applying\\_PPN\\_06\\_21\\_\\_Selection\\_Criteria\\_\\_3\\_.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/991623/Guidance_on_adopting_and_applying_PPN_06_21__Selection_Criteria__3_.pdf)

# CARBON REDUCTION PLAN

Supplier name: Juvisé Pharmaceuticals

Publication date:

## Commitment to achieving Net Zero

In response to the pressing global challenge of climate change, Laboratoire Juvisé Pharmaceuticals (SIREN 509 059 879) is committed to achieving Net Zero emissions by 2050. As such, Juvisé Pharmaceuticals has engaged in the following project to calculate, report, and identify opportunities to reduce its greenhouse gas (GHG) emissions.

Juvisé Pharmaceuticals' operations are primarily located in France, with a negligible footprint in the UK. The data reported here includes the global operations.

This report, in accordance with PPN 06/21, details the results of Juvisé Pharmaceuticals' GHG inventory, which quantified GHG emissions across the reporting period of 1/01/24 - 31/12/2024. Also documented is Juvisé Pharmaceuticals' long-term strategy to monitor, manage, and minimise its environmental impact in alignment with achieving its ambitious Net Zero commitment.

This first published report was prepared with the support of Ecologi to ensure that emissions were quantified in alignment with the Greenhouse Gas Protocol Corporate Accounting and Reporting Standard and supplementary Corporate Value Chain (Scope 3) Standard.

## Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

**Baseline Year: 2023**

### Additional Details relating to the Baseline Emissions calculations.

Juvisé Pharmaceuticals was responsible for the internal management controls governing the collection and entry of data for processing. The subsequent emissions calculation was conducted by R3 Group on behalf of Juvisé Pharmaceuticals and reviewed by Ecologi. This report was then generated with the support of Ecologi in accordance with the Greenhouse Gas Protocol Corporate Accounting and Reporting Standard and supplementary Corporate Value Chain (Scope 3) Standard.

Emissions have been calculated using the appropriate emission conversion factors, both from Ademe and the UK government, Department for Energy Security and Net Zero (DESNZ). These are supplemented by emissions factors from Small World Consulting's environmentally extended MRIO dataset, used for spend-based emissions calculations. The methodology for homeworking emissions aligns with Anthesis' published in their 2021 White Paper.

Reported emissions figures are expressed as tonnes of carbon dioxide equivalent (tCO<sub>2</sub>e) and include GHG emissions from all seven GHGs named by the Kyoto

Protocol: CO<sub>2</sub>, N<sub>2</sub>O, CH<sub>4</sub>, HFCs, PFCs, SF<sub>6</sub> and NF<sub>3</sub>.

The GHG inventory assesses emissions for the reporting period 1/01/24 - 31/12/2024.

The boundary of the report includes all global operations (including UK) during the reporting period. An operational control approach<sup>4</sup> has been adopted, and emissions are categorised within the relevant Scope, as prescribed by the GHG Protocol.

Scope 1 and Scope 2 emissions have been reported in accordance with requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.

Please note, absolute emissions have increased due to a new product acquisition and business expansion. Juvisé Pharmaceuticals experienced a global increase in FTE of 23.4% and a total net sales increase of +43% from 2023 to 2024. For context, Juvisé had no commercial presence in the UK in 2023. Juvisé Pharmaceuticals acquired Pylera® in 2022 and Ponvory® in 2024, with both products generating their first sales in the UK in 2024.

**Baseline year emissions: 2023**

<b>EMISSIONS TOTAL</b>	<b>633.37 (tCO<sub>2</sub>e)</b>
<b>Scope 1</b>	<b>0</b>
<b>Scope 2</b>	<b>1.04</b>
<b>Total Scope 3*</b>	<b>632.33</b>
<b>Scope 3 - Category 4: Upstream transportation and distribution</b>	<i>435.00</i>
<b>Scope 3 - Category 5: Waste generated in operations</b>	<i>1.57</i>
<b>Scope 3 - Category 6: Business travel</b>	<i>1.32</i>
<b>Scope 3 - Category 7: Employee commuting (including homeworking)</b>	<i>12.92</i>
<b>Scope 3 - Category 13: Downstream transportation and distribution</b>	<i>163.52</i>

\*Only mandatory categories are reported

<sup>4</sup> A company has operational control over an operation if it, or one of its subsidiaries, has the full authority to introduce and implement its operating policies at the operation. Under the operational control approach, a company accounts for 100% of emissions from operations where it has operational control.

## Current Emissions Reporting

Reporting Year: 2024	
<b>EMISSIONS TOTAL</b>	<b>640.72(tCO<sub>2</sub>e)</b>
<b>Scope 1</b>	<b>0.00</b>
<b>Scope 2</b>	<b>2.13</b>
<b>Scope 3*</b>	<b>638.59</b>
<b>Scope 3 - Category 4:Upstream transportation and distribution</b>	<b>444.98</b>
<b>Scope 3 - Category 5: Waste generated in operations</b>	<b>1.61</b>
<b>Scope 3 - Category 6: Business travel</b>	<b>27.18</b>
<b>Scope 3 - Category 7: Employee commuting (including homeworking)</b>	<b>12.4</b>
<b>Scope 3 - Category 13: Downstream transportation and distribution</b>	<b>152.35</b>

\*Only mandatory categories are reported


## Emissions reduction targets

In alignment with the UK Government's 2050 Net Zero targets and global efforts to limit global warming and the worst effects of climate change, Juvisé Pharmaceuticals is committed to achieving Net Zero emissions across the entire value chain (Scopes 1, 2, and 3) by 2050. Where possible, ambitious emissions reduction actions will be implemented to advance the achievement of Net Zero.

Juvisé Pharmaceuticals' projected emissions reduction activities include but are not limited to:

- Reducing Freight Emissions
- Engaging with Suppliers
- Improving the reporting of GHG emissions
- Reducing Energy Consumption & Waste Production
- Redefining our travel policy

In order to continue its progress to achieving Net Zero, Juvisé Pharmaceuticals has adopted the following carbon reduction targets.



\*2023 and 2024 calculated emissions

## Completed Carbon Reduction Initiatives

The emissions measurements for 2023 and 2024 were carried out immediately after each other in 2025. As this is the first year of reporting, reduction projects are being initiated, so there are no completed reduction projects or overall reduction targets yet. Instead, Juvisé Pharmaceuticals has focused on planning the following emissions reduction projects.

## Carbon Reduction Projects

Juvisé Pharmaceuticals is committed to embedding sustainable practices within its global business operations to mitigate environmental impact. As part of its first carbon footprint assessment, this document outlines an initial set of decarbonisation initiatives contributing to Juvisé Pharmaceuticals' roadmap towards Net Zero across its entire value chain. While this marks an important first step, the company recognises the need for continuous improvement over time.

The proposed interventions include both short- and long-term actions, reflecting Juvisé Pharmaceuticals' commitment to progressively enhancing its strategy and achieving its overarching Net Zero ambition. In the future we hope to implement further measures such as:

**1. Reducing Freight Emissions:** Juvisé Pharmaceuticals is proactively working to reduce its overall impact from freight. To do so, we will:

- Audit and optimise our internal freight management
- Conduct an environmental impact assessment of the relocation of Pylera® drug manufacturing from Canada to Europe

**2. Engaging with Suppliers:** Juvisé Pharmaceuticals aims to establish criteria to better understand and assess suppliers' CSR commitments, particularly regarding carbon reduction, in order to work with partners who share its sustainability goals.

**3. Improving the reporting of GHG emissions:** Juvisé Pharmaceuticals is committed to refining the reporting of GHG emissions by annually recalculating its Scope 1, 2, and 3 carbon footprint and restructuring internally held data to enable more granular data collection.

**4. Reducing Energy Consumption & Waste Production:** Juvisé Pharmaceuticals is proactively working to reduce the overall energy consumption and waste production across company sites located in France.

**Expected reduction:** 15% reduction in consumption and a switch to 100% renewable energy

**5. Redefining the travel policy:** Juvisé Pharmaceuticals is committed to reducing emissions from employee commuting and business travel. Elements of this travel policy include:

- Adopting a policy favouring train over plane for all trips under 4 hours by rail
- Raising employee awareness of the impact of business travel
- Implementing the Sustainable Mobility Package aimed at promoting sustainable employee commuting

**Expected reduction:** 15% of travel related emissions

## Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standards for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard<sup>5</sup> and uses the appropriate Government emission conversion factors for greenhouse gas company reporting<sup>6</sup>.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions has been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard<sup>7</sup>.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

## Signed on behalf of Juvisé Pharmaceuticals

Name: **Emilie GOUNON**

Position: General Manager

Date: février 16, 2026 | 5:13 AM PST

Signature:

Signé par :  
  
5498C5564BE14C3...

<sup>5</sup> <https://ghgprotocol.org/corporate-standard>

<sup>6</sup> <https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

<sup>7</sup> <https://ghgprotocol.org/standards/scope-3-standard>